KNSA: Kiniksa Pharmaceuticals O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati
Algoritmlar yordamida yallig'lanishga qarshi agentlar sintezini avtomatlashtiradigan biznesga investitsiya kiritishga arziydimi? PEG momentum ko'rsatkichi bunga javob beradi va 0.85 ushbu parametrning joriy holatini aks ettiradi. Kiniksa Pharmaceuticals (KNSA) barqarorligi kamyob patologiyalar uchun turli terapevtik yechimlar bilan ta'minlangan. Innovatsiya vektori tasdiqlangan molekulalarning qo'llanilishini kengaytirish va interleykin inhibitorlarini chiqarishga qaratilgan. Ushbu grafik dinamikasi bozor shovqinini haqiqiy pul oqimlaridan ajratishga yordam beradi.
Kiniksa Pharmaceuticals (KNSA) kompaniyasi koʻrsatkichlari kesimi va tahlili
- aksiya narxi va baholash bo'yicha konsensus prognoz:
- bozor kapitallashuvi haqida ma'lumot:
- kompaniyaning balans qiymati tafsilotlari:
- emitentning kredit yuki va likvidlik ko'rsatkichlari:
Umumiy qarzning kapitalga nisbati Kiniksa Pharmaceuticals|KNSA - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati ko'rsatkichi kiniksa.com|KNSA - Kompaniyaning jamlangan qarzlari|Balans qiymatiga qarzlar Kiniksa Pharmaceuticals Ltd|KNSA - Kompaniyaning uzoq muddatli qarzi|Kompaniyaning qisqa muddatli qarzlari Kiniksa|Oraliq qoplama koeffitsiyenti kiniksa.com
- biznes foydasi va investitsiya koeffitsiyentlari ma'lumotlari:
KNSA - Kompaniyaning sof foydasi|Sof foyda prognozi Kiniksa Pharmaceuticals|KNSA - P/E multiplikatori|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Kiniksa Corp|KNSA - Narxning foydaga va o‘sish sur’atiga nisbati|EV/EBITDA multiplikatori Kiniksa Pharmaceuticals Ltd|KNSA - Foizlar, soliqlar va eskirish to'lanishidan oldingi foyda|So'nggi to'rtta chorak uchun bir aksiya uchun sof foyda Kiniksa|KNSA - Bir aksiya uchun sof foyda (EPS TTM)|Choraklik EPS foyda o'sishi kiniksa.com|KNSA - Bu yil bir aksiya uchun sof foyda o'sishi|Keyingi yilda bir aksiya uchun foydaning kutilayotgan dinamikasi Kiniksa Pharmaceuticals
- umumiy tushum va sotuv hajmi ma'lumotlari:
Kompaniyaning umumiy tahlili:KNSA - Kiniksa Pharmaceuticals, Ltd.
Kiniksa Pharmaceuticals (KNSA) strategik autsorsing orqali biologik ishlab chiqarishni kengaytirmoqda, bu esa kapital xarajatlarini va operatsion xatarlarni minimallashtiradi. PEG o'sish aksiyalar ko'rsatkichi tomonidan ko'rsatilgan foyda o'sishiga nisbatan P/E koeffitsiyenti, tushumlar dinamikasiga nisbatan bozor qiymatining adolatli ekanligini baholash imkonini beradi, bunda birdan past qiymat aktivning yetarlicha baholanmaganligini va tez o'sish potentsialiga ega ekanligini anglatadi.
Kiniksa Pharmaceuticals raqobatchilari
ARGX (argenx N.V.) - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|PEG multiplikatori BNTX (BioNTech Group)|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati Abivax (ABVX)|ADMA - Narxning foydaga va o‘sish sur’atiga nisbati|protagonist-inc.com (PTGX) - Narx-foyda va o‘sish multiplikatori|Immunovant (IMVT) - Narxning foydaga va o‘sish sur’atiga nisbati|Narx-foyda va o‘sish multiplikatori Grifols SA|Narx-foyda va o‘sish multiplikatori ADPT|PEG multiplikatori Celldex Corp|Narxning foydaga va o‘sish sur’atiga nisbati Aurinia Pharmaceuticals (AUPH)|biocryst.com - O‘sishni hisobga olgan narx-foyda koeffitsiyenti|PEG multiplikatori VERA (Vera Therapeutics)|Dianthus Therapeutics Inc (DNTH) - O‘sish sur’atiga tuzatilgan narx-foyda|PHVS - Narxning foydaga va o‘sish sur’atiga nisbati|ABCL - PEG multiplikatori|TRML: PEG multiplikatori|PGEN - O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati|Narxning foydaga va o‘sish sur’atiga nisbati Pharming Group|O‘sishni hisobga olgan narx-foyda koeffitsiyenti NKTR (Nektar Therapeutics Inc)|PEG multiplikatori UPB|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati Zenas Corp|Narxning foydaga va o‘sish sur’atiga nisbati Immunome, Inc. IMNM|PEG multiplikatori gossamerbio.com GOSS|KALV - Narxning foydaga va o‘sish sur’atiga nisbati|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati Septerna, Inc. SEPN|PVLA: PEG multiplikatori|Savara Pharma (SVRA) - PEG multiplikatori|Narx-foyda va o‘sish multiplikatori RIGL|ANAB: O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|Narxning foydaga va o‘sish sur’atiga nisbati Astria Therapeutics, Inc. (ATXS)|ENGN: Kapitalizatsiyaning foyda va o‘sish sur’atiga nisbati|PEG multiplikatori RAPT (RAPT Therapeutics, Inc.)|O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti JBIO|Aclaris Therapeutics - PEG multiplikatori|KYTX - PEG multiplikatori|Tiziana Life Sciences Ltd (TLSA) - Narxning foydaga va o‘sish sur’atiga nisbati|Cabaletta Bio Inc. - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|Narxning foydaga va o‘sish sur’atiga nisbati Ventyx Bio|Narx-foyda va o‘sish multiplikatori Theratechnologies, Inc (THTX)|PEG multiplikatori AVTX|PEG multiplikatori eledon.com (ELDN)|PEG multiplikatori AGEN (Agenus Inc.)|CLYM - Narx-foyda va o‘sish multiplikatori|Zura Bio Limited - PEG multiplikatori|O‘sish sur’atiga tuzatilgan narx-foyda aTyr Pharmaceuticals|ADAG (adagene.com) - Narx-foyda va o‘sish multiplikatori|Ikena Oncology (IMA) - PEG multiplikatori|Narx-foyda va o‘sish multiplikatori STTK|EQ (Equillium Bio) - Kompaniya qiymatining foyda o‘sish sur’atiga nisbati|PEG multiplikatori CNTB|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati immunic-therapeutics.com|PEG multiplikatori ATRA (Atara Bio)|IFRX - Narx-foyda va o‘sish multiplikatori|X4 Pharmaceuticals, Inc. - PEG multiplikatori|ACET - PEG multiplikatori|celularity.com (CELU) - Narxning foydaga va o‘sish sur’atiga nisbati|INMB (INmune Bio Corporation) - Narxning foydaga va o‘sish sur’atiga nisbati|Narxning foydaga va o‘sish sur’atiga nisbati Barinthus Biotherapeutics|kezarlifesciences.com (KZR) - O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati|Narxning foydaga va o‘sish sur’atiga nisbati SAB Biotherapeutics, Inc. (SABS)|PEG multiplikatori Akari Therapeutics PLC (AKTX)|Narxning foydaga va o‘sish sur’atiga nisbati Enlivex Therapeutics Ltd. ENLV|QTTB: O‘sishni hisobga olgan narx-foyda koeffitsiyenti|GOVX - Narxning foydaga va o‘sish sur’atiga nisbati|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati edesabiotech.com EDSA|IBIO: PEG multiplikatori|Carisma Therapeutics Inc. (CARM) - PEG multiplikatori|Narxning foydaga va o‘sish sur’atiga nisbati XTL Biopharmaceuticals, Ltd.|Bolt Bio - Kapitalizatsiyaning foyda va o‘sish sur’atiga nisbati|PEG multiplikatori HCWB|APVO (aptevotherapeutics.com) - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|PEG multiplikatori AIM (AIM ImmunoTech)|PEG multiplikatori Aditxt Inc. ADTX|GRI - Narxning foydaga va o‘sish sur’atiga nisbati|O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti XRTX (XORTX Corp)|Vyome Holdings Inc (HIND) - Narxning foydaga va o‘sish sur’atiga nisbati|Narx-foyda va o‘sish multiplikatori revbiosciences.com|INDP (Indaptus Therapeutics, Inc.) - PEG multiplikatori|PEG multiplikatori Scinai Immunotherapeutics Ltd|Narx-foyda va o‘sish multiplikatori CALI (CalciMedica, Inc.)|AFMD (affimed.com) - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|PEG multiplikatori ALLK (Allakos)|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati HOOKIPA Pharma, Inc. (HOOK)|IGMS - Narxning foydaga va o‘sish sur’atiga nisbati|iTeos Therapeutics Inc (ITOS) - Narx-foyda va o‘sish multiplikatori|Ocean Bio (OCEA) - Narxning foydaga va o‘sish sur’atiga nisbati|Narx-foyda va o‘sish multiplikatori TC BioPharm Ltd|Narx-foyda va o‘sish multiplikatori THRD
